Gastroenterology
Volume 139, Issue 1 , Pages 93-101, July 2010

Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients

  • Douglas A. Corley

      Affiliations

    • Kaiser Permanente Division of Research, Oakland
    • Kaiser Permanente Medical Center, San Francisco, California
    • Corresponding Author InformationReprint requests Address requests for reprints to: Douglas A. Corley, MD, PhD, Kaiser Permanente Division of Research, 2000 Broadway, Oakland, California 94612. fax: (510) 891-3606
  • ,
  • Ai Kubo

      Affiliations

    • Kaiser Permanente Division of Research, Oakland
  • ,
  • Wei Zhao

      Affiliations

    • Kaiser Permanente Division of Research, Oakland
  • ,
  • Charles Quesenberry

      Affiliations

    • Kaiser Permanente Division of Research, Oakland

Received 13 August 2009; accepted 25 March 2010. published online 29 March 2010.

Background & Aims

Drugs that inhibit gastric acid might increase the risk of hip fracture. However, little long-term exposure data exist and no large studies have been conducted in the United States.

Methods

We conducted a case-control study using data from an integrated health services organization. We evaluated 33,752 patients with incident diagnoses of hip/femur fractures (cases), 130,471 matched members without fractures (controls), prescription data for use of proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) (up to 10 years' cumulative duration), and confounders.

Results

Patients with hip fractures were more likely than controls to have previously received a ≥2-year supply of PPIs (odds ratio [OR], 1.30; 95% confidence interval [CI], 1.21–1.39) or H2RAs (OR, 1.18; 95% CI, 1.08–1.29). The risk was reduced after discontinuation of medication (OR of 1.30 [95% CI, 1.21–1.41] for current PPI users vs OR of 1.09 [95% CI, 0.64–1.85] for patients who received their last prescription 2–2.9 years ago). Higher dosages (but not increasing cumulative durations) were associated with increased risk (eg, ≥1.5 pills/day: OR, 1.41 [95% CI, 1.21–1.64]; <0.74 pills/day: OR, 1.12 [95% CI, 0.94–1.33]). Excess fracture risk for PPI use was only present among persons with at least one other fracture risk factor.

Conclusions

Use of drugs that inhibit gastric acid is associated with an increased risk of hip fracture; however, this association was only found among persons with at least one other risk factor for hip fracture. Acid inhibition might therefore be associated with fracture risk in persons already at risk for osteoporosis, although other confounding cannot be excluded.

Keywords: Calcium, Bone, Medication, Gastroesophageal Reflux

Abbreviations used in this paper: CI, confidence interval, GERD, gastroesophageal reflux disease, H2RA, histamine-2 receptor antagonist, ICD-9, International Statistical Classification of Diseases, 9th Revision, KPNC, Kaiser Permanente, Northern California, OR, odds ratio, PPI, proton pump inhibitor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 View this article's video abstract at www.gastrojournal.org.

 Conflicts of interest The authors disclose the following: Dr Corley has received research funding (unrelated to the current project) from Wyeth Pharmaceuticals, which manufacturers a proton pump inhibitor. He does not have stock, consulting arrangements, or any other relationship with Wyeth. The remaining authors disclose no conflicts.

 Funding Supported by a Kaiser Permanente Community Benefits Grant and US National Institutes of Health grant R01 DK63616 (to D.A.C.).

PII: S0016-5085(10)00488-9

doi:10.1053/j.gastro.2010.03.055

Gastroenterology
Volume 139, Issue 1 , Pages 93-101, July 2010